Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.36 |
| ▸ | PPARA | Q07869 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260909 | 0.82 | PTPN1 (0.48) | KDM4EALOX5PTPN1MEN1KMT2A | |
| SCHEMBL4265420 | 0.81 | PTPN1 (0.59) | KDM4EALOX5PTPN1MEN1KMT2A | |
| SCHEMBL4263227 | 0.78 | MEN1 (0.51) | KDM4EALOX5PTPN1MEN1KMT2A | |
| SCHEMBL4270351 | 0.76 | PTPN1 (0.46) | KDM4EALOX5PTPN1MEN1KMT2A | |
| SCHEMBL4275296 | 0.75 | PPARG (0.50) | KDM4EALOX5PTPN1MEN1KMT2A | |
| SCHEMBL4259861 | 0.75 | KDM4E (0.46) | KDM4EALOX5PTPN1MEN1KMT2A | |
| SCHEMBL27046580 | 0.70 | ALOX5 (0.54) | KDM4EALOX5GGPS1 | |
| SCHEMBL16804571 | 0.69 | ALOX5 (0.56) | ALOX5GGPS1 | |
| SCHEMBL16582801 | 0.69 | ALOX5 (0.70) | KDM4EALOX5MEN1KMT2AALDH1A1 | |
| SCHEMBL16804578 | 0.68 | ALOX5 (0.55) | ALOX5GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146574-A1 | Heterocycle Substituted Carboxylic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2008-06-19 | — | — | US | disclosed |
| US-7329680-B2 | Heterocycle substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1628970-A2 | HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | The Institutes of Pharmaceutical Discovery, LLC (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050004114-A1 | Heterocycle substituted carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2005-01-06 | — | — | US | disclosed |
| WO-2004099192-A2 | HETEROCYCLE SUBSTITUTED CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES OF PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004114-A1 | Heterocycle substituted carboxylic acids | PTPRC, PTPRS, PTPRJ | KDM4E 1427/4885ALOX5 1318/4885PTPN1 15/4885 |
| US-20080146574-A1 | Heterocycle Substituted Carboxylic Acids | PTPRC, PTPRS, PTPRJ | KDM4E 1427/4885ALOX5 1318/4885PTPN1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.